Tropomyosin receptor kinase antagonism in cylindromatosis
| ISRCTN | ISRCTN75715723 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN75715723 |
| Secondary identifying numbers | 17398 |
- Submission date
- 22/10/2014
- Registration date
- 22/10/2014
- Last edited
- 02/07/2018
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Skin and Connective Tissue Diseases
Plain English summary of protocol
Background and study aims
This study aims to evaluate a new ointment to treat an inherited skin tumour condition called cylindromatosis. Patients from families with this condition carry an error in their DNA (CYLD mutation) that results in the development of multiple skin tumours on the face, scalp and trunk. These tumours are disfiguring, can be painful, and may ulcerate and bleed. Surgery is the only available treatment, and up to 1 in 4 patients with this condition undergo removal of their entire scalp to manage this condition. We have recently discovered an abnormal signal in the tumour cells called TRK. This signal is recognised to give tumour cells the ability to survive, and in laboratory tests blocking it with drugs called TRK inhibitors results in the tumour cells dying. We propose a study of an ointment form of TRK inhibitor as a means to reduce tumour growth in these patients. We have partnered with a drug company (Creabilis) who have already produced this ointment (called CT327) for trials in skin conditions. Should this be effective, it potentially could be used by patients in the future to treat early tumours and reduce the number of operations they would otherwise undergo.
Who can participate?
Patients aged 18 and over from families with known CYLD mutations, who are scheduled to have a tumour removed.
What does the study involve?
This is a two-part study. In part 1 participants are provided with active CT327 ointment and a spatula to help them to apply the correct amount of ointment. The dose is one application (two spatulas) in the evening to the selected tumour (scheduled for removal) as directed. The aim of part 1 is to determine the safety of CT327 in CYLD mutation carriers. The number of patients who experience severe treated skin site reactions is measured over a 4-week period. In part 2 participants are randomly allocated to one of two groups and provided with active CT327 and placebo (dummy) ointment. One group applies the active ointment to tumours on the right side of their body and placebo ointment to the left side. The other group applies the placebo ointment to tumours on the right side of their body and active ointment to the left side. The dose is one application (one spatula) in the evening to each selected tumour (4-5 on each side) as directed. The number of tumours responding to treatment is measured after 12 weeks.
What are the possible benefits and risks of participating?
Not provided at time of registration
Where is the study run from?
Royal Victoria Infirmary (UK)
When is the study starting and how long is it expected to run for?
October 2014 to November 2016
Who is funding the study?
Wellcome Trust (UK)
Who is the main contact?
Amy Cranston
amy.cranston@ncl.ac.uk
Contact information
Scientific
Clinical Research Facility
4th Floor Leazes Wing
Royal Victoria Infirmary
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
United Kingdom
| amy.cranston@ncl.ac.uk |
Study information
| Study design | Both; Interventional; Design type: Treatment |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | Topical tropomysin kinase (TRK) inhibitor as a treatment for inherited CYLD-defective skin tumours (TRAC) |
| Study acronym | TRAC |
| Study objectives | Repurposing study, using CT327 ointment, previously used in patients with psoriasis and eczema, in patients with CYLD defective skin tumours in a 2 part clinical trial to determine safety and investigate if the tumours reposed to CT327. |
| Ethics approval(s) | NRES Committee North East - Tyne and Wear South, 04/09/2014, ref: 14/NE/1080 |
| Health condition(s) or problem(s) studied | Topic: Cancer, Genetics, Dermatology; Subtopic: Head and Neck Cancer, Genetics Research and Congenital Disorders (all subtopics), Skin (all Subtopics); Disease: Head and Neck, Genetics Research and Congenital Disorders, Dermatology |
| Intervention | Cohort 1: active trial medication containing CT327 at 0.5%w/w will be provided as ointment in 20 g glass jars. Patients will be provided with a spatula to help them to apply the correct amount of ointment. The dose will be one application (2 standardised spatulas) in the evening to the selected tumour (scheduled for excision) as directed. Cohort 2: patients will be randomised to either right side active and left side placebo (RALP) or right side placebo, left side active (RPLA) and allocated a kit of treatment. Active and placebo trial medication will be provided at baseline and visit 4 to supply enough ointment for the 12 week period. The dose will be one application (1 standardised spatula) in the evening to each selected tumour (4-5 on each side) as directed. |
| Intervention type | Other |
| Primary outcome measure | Cohort 1: Number of patients with severe treated skin site reactions as determined by Modified Draize score. Cohort 2: The proportion of tumours responding to treatment by 12 weeks. |
| Secondary outcome measures | Cohort 1: 1. Patient reported quality of life using patient reported QoL tools (EQ5D, DLQI) 2. Acceptability of treatment according to patient treatment questionnaire 3. Adverse events within a planned 4-week treatment period 4. Compliance including reasons for non-compliance Cohort 2: 1. Change in tumour volume from baseline (pre-randomisation) to 12 weeks 2. Adverse events within a planned 12-week treatment period 3. Compliance including reasons for non-compliance 4. Confirmation of the definition of response (currently according to WHO RECIST criteria where response is defined as >30% reduction in tumour volume, this will be used as a benchmark) 5. Expression of targets of TRK signalling in tumour biopsies as determined by QPCR and immunohistochemistry 6. Patient reported quality of life using patient reported QoL tools (EQ5D, DLQI) 7. Assessment of acceptability of trial treatment according to patient treatment questionnaire |
| Overall study start date | 01/10/2014 |
| Completion date | 30/11/2016 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 28; UK Sample Size: 28 |
| Key inclusion criteria | Cohort 1: 1. Males and females age 18 years and older 2. Patients from genotyped pedigrees with known CYLD mutations; or if they have a clinical phenotype compatible with this diagnosis 3. Patients that are suitable for the trial will have at least one eligible tumour 4. The eligible tumour will be scheduled for removal >4 weeks from consent 5. The eligible tumour must be no more than 3cm in size 6. For women of childbearing age: a negative pregnancy test is required prior to study entry, and on completion of trial treatment. The patient must be using an adequate contraception method and agree to continue using this throughout the trial and for at least 2 weeks after stopping trial medication 7. Sexually active men must agree to use barrier forms of contraception 8. The recruiting clinician must be confident that the patient understands the consent process and has the capacity and willingness to provide fully informed consent for participation in the trial Cohort 2: 1. Males and females age 18 years and older 2. For women of child bearing age: a negative pregnancy test is required prior to study entry, and on completion of trial treatment. The patient must be using an adequate contraception method and agree to continue using this throughout the trial and for at least 2 weeks after stopping trial medication 3. Patients from genotyped pedigrees with known CYLD mutations, or if they have a clinical phenotype compatible with this diagnosis 4. Patients will optimally have 8-10 eligible tumours 5. Eligible tumours will be less than 1 cm in diameter and no more than 2 cm in diameter at the base 6. Eligible tumours must be spaced at least 1 cm apart from other eligible tumours to avoid crosscontamination 7. The recruiting clinician must be confident that the patient understands the consent process and has the capacity and willingness to provide fully informed consent for participation in the trial 8. Patients who have completed Phase 1b without adverse reaction and after completing a minimum 2 week treatment free washout period |
| Key exclusion criteria | Cohort 1: 1. Patients aged <18 years 2. Patients without CYLD defective tumours 3. CYLD defective tumours which are ulcerated (these tumours will be managed according to standard practice of care) 4. The eligible tumour is due to be removed <4 weeks from consent 5. Pregnancy or lactation 6. Women of childbearing age and sexually active men whom do not wish to use contraception whilst on the study 7. Severe incapacity of higher function such that fully informed consent cannot be achieved, to be determined by clinical judgement 8. Use of any other topically administered treatments at the treatment site Cohort 2: 1. Patients aged <18 years 2. Patients without multiple CYLD defective tumours 3. Pregnancy or lactation 4. Women of childbearing age and sexually active men whom do not wish to use contraception whilst on the study 5. CYLD defective tumours which are ulcerated, have recently changed or are painful (these tumours will be managed according to standard practice of care) 6. Severe incapacity of higher function such that fully informed consent cannot be achieved, to be determined by clinical judgement 7. Significant concurrent illness 8. Patients who developed an adverse reaction to CT327 in cohort 1(score of 4 or above on the modified Draize score) 9. Patients who have taken part in cohort 1and not completed a minimum 2 week treatment free washout period 10. Large tumours >2cm base diameter will not be eligible 11. Any tumour within 10cm of an excision scar of a cohort 1 treated site will not be eligible 12. Use of any other topically administered treatments at the treatment site |
| Date of first enrolment | 01/10/2014 |
| Date of final enrolment | 30/11/2016 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
NE1 4LP
United Kingdom
Sponsor information
Hospital/treatment centre
Leazes Wing
Royal Victoria Infirmary
Queen Victoria Road
Newcastle Upon Tyne
NE1 4LP
England
United Kingdom
"ROR" |
https://ror.org/05p40t847 |
|---|
Funders
Funder type
Charity
Private sector organisation / International organizations
- Location
- United Kingdom
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | protocol | 07/03/2017 | Yes | No | |
| Results article | results | 01/08/2018 | Yes | No | |
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
02/07/2018: Publication reference added.
09/03/2017: Publication reference added.
